Yahoo Quote | Big Chart | Company Website | Yahoo News | PinkSheets

For Wednesday August 6th, 2008

THIS JUST IN....

US Aircraft Carrier, The Ronald Reagan, Sets Sail for Gulf Deployment with Techalt's Stan's Rodeo Ointment

SEATTLE--(BUSINESS WIRE)--Techalt, Inc. (Pink Sheets: TCLT - News) (”Techalt” or the “Company”) announced today that Navy personal aboard the USS Ronald Reagan are using its’ product, Stan’s Rodeo Ointment (“SRO”), as a healing ointment to repair abrasions incurred in connection with the fulfillment of their duties. David Moore, CEO of Techalt stated, “For the past eighteen months, the US Naval Medical staff of the USS Ronald Reagan has been using Stan’s Rodeo Ointment to treat Naval Personnel. The military’s utilization of our licensed product further demonstrates its effectiveness and, ultimately, its broad OTC applications.” The USS Ronald Reagan deployed in May 2008 for a six-month tour to support the efforts in the war in Iraq.

The USS Reagan's Chief Surgeon, Dr. George Linville, began using SRO in January 2007 on cuts, scrapes, blisters, and skid burns that sailors and aircrew received from their demanding duties. Prior to the Gulf deployment, Dr. Linville stated, “SRO has the highest efficacy of any topical ointment I have ever used. In my 30 years of treating wounds I have never had an ointment that heals wounds like this.” SRO is currently undergoing acceptance into the medical supply list for all branches of the US military.

Techalt is currently in the process of identifying financing for expanding the distribution of SRO to other customers. Furthermore, Techalt is seeking to secure (i) additional contracts and (ii) over-the-counter approval from the United States Food and Drug Administration. Once SRO has received approval to be distributed as an over-the-counter product, SRO will compete in the same product sector as Neosporin, which realized approximately $22,000,000 in gross revenue in its first year of over-the-counter distribution.

About Stan’s Rodeo Ointment (“SRO”):

SRO is a sports cream product designed to accelerate the healing time for abrasions, lacerations, blisters and other open wounds to the skin, while diminishing the pain that often results from such injuries. Developed by Stanley Johnston, former head athletic trainer for the Los Angeles Dodgers, SRO is currently available by prescription and used by several prominent Olympic and professional athletes. Techalt also acquired the rights to develop Stan’s Blister Rub (“SBR”), which is a combination of materials that strengthen the skin after it has healed to reduce the likelihood of the reoccurrence of blisters to the applied area. Patent protection has been filed covering the formulations and processing of SRO with the US Patent and Trademark Office with a patent expected in August 2008.

About Techalt:

Techalt’s business model as a public holding company is to pursue quality opportunities in developing early to mid-stage alternative technology, communications, environmental and health and wellness companies.

Company Essentials:

Symbol
TCLT
Stock Price Open
$0.0001  Volume: 51,312,800
52 Week Range

$0.0001 - $0.029
Website
http://www.techalt.com/
Quote
http://finance.yahoo.com/q?s=TCLT.PK

 
Fill out the form below to get regular information updates on TCLT and other stocks.

Name: - Email Address:   
 

DISCLAIMER:

This profile is not without bias, and is a paid release. IWSR has been compensated for dissemination of company information on behalf of a third party. (IWSR has been compensated 25,000,000 Free Trading Shares for the coverage of Techalt, Inc. (Pink Sheets:TCLT) from a third party. IWSR holds no shares of the stock. IWSR may receive shares for extension of its services. Any shares will be disclosed at such time that IWSR is aware of a clients desire to extend the original services. IWSR may have received shares of a company profiled in this release prior to the dissemination of the information in this release. IWSR may immediately sell some or any shares in a profiled company held by IWSR and may have previously sold shares in a profiled company held by IWSR. IWSR's services for a company may cause the company's stock price to increase, in which event IWSR would make a profit when it sells its stock in a company. In addition, IWSR's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and IWSR undertakes no obligation to update such statements.